Catalyst Pharmaceuticals, Inc. $CPRX Stake Raised by Systematic Financial Management LP

Systematic Financial Management LP boosted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 723,242 shares of the biopharmaceutical company’s stock after acquiring an additional 37,578 shares during the quarter. Systematic Financial Management LP’s holdings in Catalyst Pharmaceuticals were worth $16,880,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CPRX. Rothschild Investment LLC lifted its position in shares of Catalyst Pharmaceuticals by 1,085.7% during the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,520 shares during the last quarter. Larson Financial Group LLC lifted its position in shares of Catalyst Pharmaceuticals by 552.7% during the 4th quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 1,564 shares during the last quarter. Advisory Services Network LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $39,000. Quarry LP acquired a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $40,000. Finally, Financial Life Planners acquired a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $42,000. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Trading Down 0.1%

NASDAQ CPRX opened at $31.26 on Friday. The stock’s 50-day moving average price is $26.81 and its two-hundred day moving average price is $24.68. The company has a market cap of $3.83 billion, a PE ratio of 17.97, a PEG ratio of 0.91 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $32.56.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on CPRX shares. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $35.00 to $31.50 in a research report on Friday, May 8th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Friday, March 27th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $32.17.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).